Haleon PLC Sponsored ADR $HLN Position Increased by Laurel Wealth Advisors LLC

Laurel Wealth Advisors LLC boosted its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 937.0% in the second quarter, Holdings Channel.com reports. The firm owned 9,914 shares of the company’s stock after purchasing an additional 8,958 shares during the period. Laurel Wealth Advisors LLC’s holdings in Haleon were worth $956,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP grew its stake in shares of Haleon by 22.0% in the 1st quarter. Wellington Management Group LLP now owns 18,700,480 shares of the company’s stock valued at $192,428,000 after buying an additional 3,372,155 shares in the last quarter. Sculptor Capital LP lifted its stake in Haleon by 22.1% in the first quarter. Sculptor Capital LP now owns 10,849,868 shares of the company’s stock valued at $111,645,000 after acquiring an additional 1,962,770 shares during the last quarter. JPMorgan Chase & Co. grew its position in Haleon by 15.5% in the second quarter. JPMorgan Chase & Co. now owns 8,776,686 shares of the company’s stock worth $91,014,000 after acquiring an additional 1,174,813 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Haleon by 6.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company’s stock worth $81,479,000 after purchasing an additional 476,823 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Haleon during the 1st quarter valued at $58,870,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on HLN shares. The Goldman Sachs Group upgraded shares of Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Barclays lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

NYSE:HLN opened at $9.59 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. The stock has a market cap of $42.69 billion, a P/E ratio of 24.58, a PEG ratio of 2.99 and a beta of 0.20. The company has a fifty day moving average price of $9.30 and a 200 day moving average price of $9.85. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.